{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:39:48Z","timestamp":1782779988086,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1136\/ijgc-2023-005170","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T12:49:58Z","timestamp":1714481398000},"page":"1196-1202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pegylated liposomal doxorubicin combined with trabectedin as a treatment option in uterine sarcomas: a single-institution retrospective analysis"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1800-7808","authenticated-orcid":false,"given":"Magdalena","family":"Steinlechner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9063-5365","authenticated-orcid":false,"given":"Laura","family":"Strobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Leitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2101-0811","authenticated-orcid":false,"given":"Teresa L.","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5064-1397","authenticated-orcid":false,"given":"Barin","family":"Feroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Marth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain G.","family":"Zeimet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-005170_bb0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.21037\/gpm-20-65","article-title":"Radiotherapy in uterine sarcoma: a narrative review of international guidelines","volume":"4","author":"Ferioli","year":"2021","journal-title":"Gynecol Pelvic Med"},{"key":"10.1136\/ijgc-2023-005170_bb0015","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3390\/clinpract11040103","article-title":"New aspects of sarcomas of uterine corpus - a brief narrative review","volume":"11","author":"Kostov","year":"2021","journal-title":"Clin Pract"},{"key":"10.1136\/ijgc-2023-005170_bb0020","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ygyno.2016.07.110","article-title":"Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: a systematic review and meta-analysis","volume":"143","author":"Bogani","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-005170_bb0025","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ygyno.2019.07.001","article-title":"Effect of adjuvant therapy on the risk of recurrence in early-stage leiomyosarcoma: a meta-analysis","volume":"154","author":"Chae","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-005170_bb0030","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1200\/EDBK_350541","article-title":"Novel therapeutics in the treatment of uterine sarcoma","volume":"42","author":"Bose","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1136\/ijgc-2023-005170_bb0035","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/annonc\/mdp485","article-title":"Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy","volume":"21","author":"Penel","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-005170_bb0040","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-005170_bb0045","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(15)70070-7","article-title":"Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial","volume":"16","author":"Pautier","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-005170_bb0050","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1055\/a-0882-4116","article-title":"Sarcoma of the uterus. Guideline of the DGGG and OEGGG (S2K level, AWMF register number 015\/074, February 2019)","volume":"79","author":"Denschlag","year":"2019","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1136\/ijgc-2023-005170_bb0055","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.ejca.2008.11.019","article-title":"Phase I clinical and pharmacokinetic study of Trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer","volume":"45","author":"Sessa","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2023-005170_bb0060","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1158\/1078-0432.CCR-08-0336","article-title":"Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma","volume":"14","author":"Blay","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2023-005170_bb0065","first-page":"2165","article-title":"The true colors of autophagy in doxorubicin-induced cardiotoxicity","volume":"18","author":"Xiao","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1136\/ijgc-2023-005170_bb0070","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/15569543.2021.1912099","article-title":"Toxic effects and molecular mechanism of doxorubicin on different organs \u2013 an update","volume":"41","author":"Renu","year":"2022","journal-title":"Toxin Reviews"},{"key":"10.1136\/ijgc-2023-005170_bb0075","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1039\/b808331m","article-title":"Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem","volume":"26","author":"Cuevas","year":"2009","journal-title":"Nat Prod Rep"},{"key":"10.1136\/ijgc-2023-005170_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29020331","article-title":"Trabectedin and lurbinectedin modulate the interplay between cells in the tumour microenvironment-progresses in their use in combined cancer therapy","volume":"29","author":"Povo-Retana","year":"2024","journal-title":"Molecules"},{"key":"10.1136\/ijgc-2023-005170_bb0085","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s12325-016-0344-3","article-title":"Trabectedin for soft tissue sarcoma: current status and future perspectives","volume":"33","author":"Gordon","year":"2016","journal-title":"Adv Ther"},{"key":"10.1136\/ijgc-2023-005170_bb0090","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00280-003-0636-6","article-title":"Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies","volume":"52","author":"Meco","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1136\/ijgc-2023-005170_bb0095","doi-asserted-by":"crossref","first-page":"6775","DOI":"10.1073\/pnas.97.12.6775","article-title":"Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation","volume":"97","author":"Jin","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/ijgc-2023-005170_bb0100","first-page":"3251","article-title":"Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells","volume":"7","author":"Takahashi","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2023-005170_bb0105","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/cncr.32795","volume":"126","author":"D\u2019Ambrosio","year":"2020","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2023-005170_bb0110","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S1470-2045(22)00380-1","article-title":"Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial","volume":"23","author":"Pautier","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-005170_bb0115","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/annonc\/mdn363","article-title":"A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies","volume":"19","author":"von Mehren","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-005170_bb0120","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00280-008-0909-1","article-title":"Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study","volume":"64","author":"Sehouli","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1136\/ijgc-2023-005170_bb0125","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1159\/000262452","article-title":"Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity","volume":"55","author":"Steppan","year":"2009","journal-title":"Chemotherapy"},{"key":"10.1136\/ijgc-2023-005170_bb0130","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/sj.bjc.6603158","article-title":"The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial","volume":"94","author":"Al-Batran","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2023-005170_bb0135","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0959-8049(01)00050-8","article-title":"Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL\/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group","volume":"37","author":"Judson","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2023-005170_bb0140","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/ijgc-2022-003764","article-title":"Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study","volume":"33","author":"Vertechy","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-005170_bb0145","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","article-title":"Doxorubicin-induced cardiomyopathy","volume":"339","author":"Singal","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-005170_bb0150","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-005170_bb0155","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/s41416-022-02108-7","volume":"128","author":"Colombo","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2023-005170_bb0160","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000312644","article-title":"High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies","volume":"56","author":"Kesterson","year":"2010","journal-title":"Chemotherapy"},{"key":"10.1136\/ijgc-2023-005170_bb0165","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ad.2021.09.003","article-title":"Alopecia, and scalp cooling systems","volume":"113","author":"Amarillo","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"10.1136\/ijgc-2023-005170_bb0170","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2011.09.019","article-title":"A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a Gynecologic Oncology Group study","volume":"124","author":"Monk","year":"2012","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24000033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24000033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-005170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T09:27:07Z","timestamp":1764062827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24000033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1048891X24000033"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-005170","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pegylated liposomal doxorubicin combined with trabectedin as a treatment option in uterine sarcomas: a single-institution retrospective analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-005170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/.","name":"copyright","label":"Copyright"}]}}